Display options
Cite
Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017;7:CD011520doi: 10.1002/14651858.CD011520.pub2.
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017). Vortioxetine for depression in adults. The Cochrane database of systematic reviews, 7CD011520. https://doi.org/10.1002/14651858.CD011520.pub2
Koesters, Markus, et al. "Vortioxetine for depression in adults." The Cochrane database of systematic reviews vol. 7 (2017): CD011520. doi: https://doi.org/10.1002/14651858.CD011520.pub2
Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev. 2017 Jul 05;7:CD011520. doi: 10.1002/14651858.CD011520.pub2. PMID: 28677828; PMCID: PMC6483322.
Copy Download .nbib Format: NLM
Share it on

Cochrane Database Syst Rev. 2017 Jul 05;7:CD011520. doi: 10.1002/14651858.CD011520.pub2.

Vortioxetine for depression in adults.

The Cochrane database of systematic reviews

Markus Koesters, Giovanni Ostuzzi, Giuseppe Guaiana, Johanna Breilmann, Corrado Barbui

Affiliations

  1. Department of Psychiatry II, Ulm University, Ludwig-Heilmeyer-Str. 2, Guenzburg, Germany, D-89312.

PMID: 28677828 PMCID: PMC6483322 DOI: 10.1002/14651858.CD011520.pub2

Abstract

BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. The mechanism of action is not fully understood, but it is claimed to be novel. Vortioxetine was placed in the category of "Other" antidepressants and may therefore provide an alternative to existing antidepressant drugs.

OBJECTIVES: To assess the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults.

SEARCH METHODS: We searched Cochrane's Depression, Anxiety and Neurosis Review Group's Specialised Register to May 2016 without applying any restrictions to date, language or publication status. We checked reference lists of relevant studies and reviews, regulatory agency reports and trial databases.

SELECTION CRITERIA: We included randomised controlled trials comparing the efficacy, tolerability, or both of vortioxetine versus placebo or any other antidepressant agent in the treatment of acute depression in adults.

DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies and extracted data. We extracted data on study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. We analysed intention-to-treat (ITT) data only and used risk ratios (RR) as effect sizes for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI). Meta-analyses used random-effects models.

MAIN RESULTS: We included 15 studies (7746 participants) in this review. Seven studies were placebo controlled; eight studies compared vortioxetine to serotonin-norepinephrine reuptake inhibitors (SNRIs). We were unable to identify any study that compared vortioxetine to antidepressant drugs from other classes, such as selective serotonin reuptake inhibitors (SSRIs).Vortioxetine may be more effective than placebo across the three efficacy outcomes: response (Mantel-Haenszel RR 1.35, 95% CI 1.22 to 1.49; 14 studies, 6220 participants), remission (RR 1.32, 95% CI 1.15 to 1.53; 14 studies, 6220 participants) and depressive symptoms measured using the Montgomery-Åsberg Depression Scale (MADRS) (score range: 0 to 34; higher score means worse outcome: MD -2.94, 95% CI -4.07 to -1.80; 14 studies, 5566 participants). The quality of the evidence was low for response and remission and very low for depressive symptoms. We found no evidence of a difference in total dropout rates (RR 1.05, 95% CI 0.93 to 1.19; 14 studies, 6220 participants). More participants discontinued vortioxetine than placebo because of adverse effects (RR 1.41, 95% CI 1.09 to 1.81; 14 studies, 6220 participants) but fewer discontinued due to inefficacy (RR 0.56, 95% CI 0.34 to 0.90, P = 0.02; 14 studies, 6220 participants). The quality of the evidence for dropouts was moderate.The subgroup and sensitivity analyses did not reveal factors that significantly influenced the results.In comparison with other antidepressants, very low-quality evidence from eight studies showed no clinically significant difference between vortioxetine and SNRIs as a class for response (RR 0.91, 95% CI 0.82 to 1.00; 3159 participants) or remission (RR 0.89, 95% CI 0.77 to 1.03; 3155 participants). There was a small difference favouring SNRIs for depressive symptom scores on the MADRS (MD 1.52, 95% CI 0.50 to 2.53; 8 studies, 2807 participants). Very low quality evidence from eight studies (3159 participants) showed no significant differences between vortioxetine and the SNRIs as a class for total dropout rates (RR 0.89, 95% CI 0.73 to 1.08), dropouts due to adverse events (RR 0.74, 95% CI 0.51 to 1.08) and dropouts due to inefficacy (RR 1.52, 95% CI 0.70 to 3.30).Against individual antidepressants, analyses suggested that vortioxetine may be less effective than duloxetine in terms of response rates (RR 0.86, 95% CI 0.79 to 0.94; 6 studies, 2392 participants) and depressive symptoms scores on the MADRS scale (MD 1.99, 95% CI 1.15 to 2.83; 6 studies; 2106 participants). Against venlafaxine, meta-analysis of two studies found no statistically significant differences (response: RR 1.03, 95% CI 0.85 to 1.25; 767 participants; depressive symptom scores: MD 0.02, 95% CI -2.49 to 2.54; 701 participants). In terms of number of participants reporting at least one adverse effect (tolerability), vortioxetine was better than the SNRIs as a class (RR 0.90, 95% CI 0.86 to 0.94; 8 studies, 3134 participants) and duloxetine (RR 0.89, 95% CI 0.84 to 0.95; 6 studies; 2376 participants). However, the sensitivity analysis casts some doubts on this result, as only two studies used comparable dosing.We judged none of the studies to have a high risk of bias for any domain, but we rated all studies to have an unclear risk of bias of selective reporting and other biases.

AUTHORS' CONCLUSIONS: The place of vortioxetine in the treatment of acute depression is unclear. Our analyses showed vortioxetine may be more effective than placebo in terms of response, remission and depressive symptoms, but the clinical relevance of these effects is uncertain. Furthermore, the quality of evidence to support these findings was generally low. In comparison to SNRIs, we found no advantage for vortioxetine. Vortioxetine was less effective than duloxetine, but fewer people reported adverse effects when treated with vortioxetine compared to duloxetine. However, these findings are uncertain and not well supported by evidence. A major limitation of the current evidence is the lack of comparisons with the SSRIs, which are usually recommended as first-line treatments for acute depression. Studies with direct comparisons to SSRIs are needed to address this gap and may be supplemented by network meta-analyses to define the role of vortioxetine in the treatment of depression.

References

  1. CNS Spectr. 2015 Oct;20(5):455-9 - PubMed
  2. Psychopharmacology (Berl). 2015 Jan;232(1):7-16 - PubMed
  3. BMJ. 2014 Jan 24;348:f7450 - PubMed
  4. Lancet. 2012 Dec 15;380(9859):2163-96 - PubMed
  5. BMJ. 2012 Jan 03;344:d8013 - PubMed
  6. J Psychopharmacol. 2012 Nov;26(11):1408-16 - PubMed
  7. Ann Intern Med. 2011 Dec 6;155(11):772-85 - PubMed
  8. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600 - PubMed
  9. Int Clin Psychopharmacol. 2005 Jan;20(1):49-52 - PubMed
  10. Syst Rev. 2013 Sep 23;2:81 - PubMed
  11. PLoS Med. 2008 Feb;5(2):e45 - PubMed
  12. BMJ. 1998 Feb 28;316(7132):690-3 - PubMed
  13. J Clin Psychiatry. 2015 May;76(5):575-82 - PubMed
  14. Asia Pac Psychiatry. 2013 Dec;5(4):231-6 - PubMed
  15. Acta Psychiatr Scand. 2011 Apr;123(4):247-65 - PubMed
  16. Int J Neuropsychopharmacol. 2014 Oct;17(10):1557-67 - PubMed
  17. Int J Epidemiol. 2002 Feb;31(1):72-6 - PubMed
  18. Arch Gen Psychiatry. 1972 Jan;26(1):57-63 - PubMed
  19. J Affect Disord. 2013 Jun;148(2-3):243-8 - PubMed
  20. Neuropsychiatr Dis Treat. 2016 Feb 29;12:523-31 - PubMed
  21. Int J Methods Psychiatr Res. 2010 Dec;19(4):211-22 - PubMed
  22. Hum Psychopharmacol. 2014 Sep;29(5):470-82 - PubMed
  23. Int Clin Psychopharmacol. 2012 Jul;27(4):215-23 - PubMed
  24. BMJ. 2014 Jan 08;348:f7668 - PubMed
  25. J Clin Psychiatry. 2012 Jul;73(7):953-9 - PubMed
  26. Psychopharmacology (Berl). 2015 Jun;232(12):2061-70 - PubMed
  27. J Clin Psychiatry. 2015 May;76(5):583-91 - PubMed
  28. Eur Neuropsychopharmacol. 2016 Jun;26(6):979-93 - PubMed
  29. Int J Clin Pract. 2014 Jan;68(1):60-82 - PubMed
  30. J Clin Psychopharmacol. 2004 Apr;24(2):126-30 - PubMed
  31. Int Clin Psychopharmacol. 2009 May;24(3):111-8 - PubMed
  32. Br J Psychiatry. 1979 Apr;134:382-9 - PubMed
  33. J Clin Epidemiol. 2006 Jan;59(1):7-10 - PubMed
  34. Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21 - PubMed
  35. J Affect Disord. 2016 May 15;196:225-33 - PubMed
  36. CNS Spectr. 2016 Apr;21(2):162-83 - PubMed
  37. Int Clin Psychopharmacol. 2015 Sep;30(5):255-64 - PubMed
  38. BMC Med. 2011 Jul 26;9:90 - PubMed
  39. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 - PubMed
  40. Curr Med Res Opin. 2013 Mar;29(3):217-26 - PubMed
  41. J Clin Epidemiol. 2011 Dec;64(12):1283-93 - PubMed
  42. Curr Psychiatry Rep. 2012 Aug;14(4):360-9 - PubMed
  43. J Psychopharmacol. 2016 Mar;30(3):242-52 - PubMed
  44. Indian J Psychiatry. 2013 Jan;55(1):41-5 - PubMed
  45. BMC Psychiatry. 2014 Sep 27;14:276 - PubMed
  46. Br J Psychiatry. 2013 Sep;203(3):179-87 - PubMed
  47. J Clin Psychiatry. 2015 Jan;76(1):8-14 - PubMed
  48. Int Clin Psychopharmacol. 2014 May;29(3):138-49 - PubMed
  49. Syst Rev. 2015 Mar 01;4:21 - PubMed
  50. Psychopharmacology (Berl). 2008 Mar;196(4):511-20; discussion 521-2 - PubMed
  51. Curr Med Res Opin. 2015 Apr;31(4):785-94 - PubMed
  52. Psychopharmacology (Berl). 2016 Jul;233(14):2813-25 - PubMed
  53. Neuropsychopharmacology. 2015 Jul;40(8):2025-37 - PubMed
  54. Eur Psychiatry. 2008 Jan;23(1):66-73 - PubMed
  55. Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91 - PubMed
  56. J Sex Med. 2015 Oct;12(10):2036-48 - PubMed
  57. Ann Pharmacother. 2002 Apr;36(4):578-84 - PubMed
  58. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851 - PubMed
  59. Arch Gen Psychiatry. 1978 Jun;35(6):773-82 - PubMed
  60. Lancet. 2009 Feb 28;373(9665):746-58 - PubMed

Substances

MeSH terms

Publication Types